GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » EPS (Diluted)

Inhibikase Therapeutics (Inhibikase Therapeutics) EPS (Diluted) : $-3.34 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics EPS (Diluted)?

Inhibikase Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.73. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.34.

Inhibikase Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.73. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.34.

Inhibikase Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.34.

During the past 3 years, the average EPS without NRIGrowth Rate was -19.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Inhibikase Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -7.70% per year. The lowest was -55.70% per year. And the median was -19.30% per year.


Inhibikase Therapeutics EPS (Diluted) Historical Data

The historical data trend for Inhibikase Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibikase Therapeutics EPS (Diluted) Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -3.42 -2.10 -4.86 -4.28 -3.57

Inhibikase Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 -1.11 -0.86 -0.64 -0.73

Competitive Comparison of Inhibikase Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Inhibikase Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibikase Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's PE Ratio falls into.



Inhibikase Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Inhibikase Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-19.029-0)/5.333
=-3.57

Inhibikase Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.65-0)/6.341
=-0.73

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhibikase Therapeutics  (NAS:IKT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Inhibikase Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Executives
Paul C Grint director 7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman director 9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman director 256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner director, 10 percent owner, officer: President and CEO 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli officer: Cheif Financial Officer
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman 10 percent owner 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339

Inhibikase Therapeutics (Inhibikase Therapeutics) Headlines

From GuruFocus